Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb withdraws European application of Opdivo plus Yervoy for first-line treatment of advanced NSCLC
A Bristol-Myers Squibb site in England. (Credit: Rept0n1x/Wikipedia.org)
A Bristol-Myers Squibb site in England. (Credit: Rept0n1x/Wikipedia.org)